Finanzen von XORTX Therapeutics Inc (XRTX)XRTXXORTX Therapeutics Inc

In the context of the broader market, XRTX competes directly with industry leaders such as GELS and PCSA. With a market capitalization of $4.51M, it holds a significant position in the sector. When comparing efficiency, XRTX's gross margin of N/A stands against GELS's N/A and PCSA's N/A. Such benchmarking helps identify whether XORTX Therapeutics Inc is trading at a premium or discount relative to its financial performance.

XORTX has shown mixed financial performance, with a recent net income of -808472 USD in Q1 2026 and a forward P/E of 0.9621, suggesting potential for recovery but also indicating ongoing losses.